Purpose: Common treatments for benign prostatic hyperplasia include 5α-reductase
inhibitors and α-adrenergic receptor antagonists. However, these treatments can only …

In men with a clinical diagnosis of benign prostatic hyperplasia (BPH), polytomous logistic
regression analysis was conducted to evaluate associations between two silent …

BACKGROUND The objective of the study was to examine associations between SRD5A2
polymorphisms and measures of benign prostatic hyperplasia (BPH). METHODS …

The prostate gland is an androgen-dependent, and polymorphisms in androgen synthesis
gene steroid 5-α reductase type II (SRD5A2) may be associated with benign prostatic …

This study aims to explore the effect of gene polymorphisms of 5a-reduction enzyme
(SRD5A2), steroidogenic cytochrome P-450 17alpha-hydroxylase (CYP17), aromatase …

PURPOSE: The SRD5A2 gene codes the steroid 5-reductase type II, a critical mediator of
androgen action, and the V89L and A49T polymorphisms of this gene may be associated …

BACKGROUND The aim of this study was to assess the impact of polymorphisms of three
genes within the androgen pathway on prostate volume, clinical parameters, and endocrine …

Objective: Previous studies have reported that rs523349 (V89L) and rs9282858 (A49T)
polymorphisms in the gene 5α-reductase II (SRD5A2) are associated with the risk of benign …

Prostate cancer is a significant cause of death in Western countries and is under the strong
influence of androgens. The steroid 5α-reductase 2 catalyzes the metabolism of testosterone …

BACKGROUND Emerging evidence indicates that testosterone (T), and not
dihydrotestosterone (DHT), is the most relevant androgen that promotes carcinogenesis in …